All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group

Issue 1716

Syndicated Loans and Leveraged Finance

  • BiVictriX Therapeutics plc, an emerging biotechnology company that develops new cancer therapies, began trading on London's alternative investment market (Aim) on Wednesday following its IPO.
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree